Derivative myelin associated glycoprotein (dMAG) results from proteolysis of transmembrane MAG and can inhibit axonal growth. We have tested the ability of certain matrix metalloproteinases (MMPs) elevated with inflammatory and demyelinating diseases to cleave MAG. We show MMP-2, MMP-7 and MMP-9, but not MMP-1, cleave recombinant human MAG. Cleavage by MMP-7 occurs at Leu 509, just distal to the transmembrane domain and, to a lesser extent, at Met 234. We also show that MMP-7 cleaves MAG expressed on the external surface of CHO cells, releasing fragments that accumulate in the medium over periods of up to 48 h or more and that are able to inhibit outgrowth by dorsal root ganglion (DRG) neurons. We conclude that MMPs may have the potential both to disrupt MAG dependent axon-glia communication and to generate bioactive fragments that can inhibit neurite growth.
Introduction
Members of the matrix metalloproteinase (MMP) family have central roles in the degradation of many extracellular matrix (ECM) components and cell surface molecules. The general features of MMP expression in the CNS are reviewed elsewhere (Avolio et al., 2003; Gasche et al., 2006; Opdenakker et al., 2003) . Various MMPs are expressed in the CNS and can be up-regulated and secreted into the extracellular space in response to growth factors, cytokines and a variety of other triggers. Excessive MMP activity can damage tissues and thus activity is usually tightly regulated, in part by naturally occurring tissue inhibitors of metalloproteinases (TIMPs). MMP and TIMP expression in the CNS is altered both in many normal physiological processes and in injury and disease.
In multiple sclerosis (MS) and various other myelin disorders, there is degradation of myelin sheathes surrounding nerve axons with potential damage to underlying nerves themselves. MMP levels are increased in MS (Anthony et al., 1997; Cossins et al., 1997; Gijbels et al., 1992; Maeda and Sobel, 1996; Ozenci et al., 2000 Ozenci et al., , 1999 Rosenberg et al., 1996; Sellebjerg et al., 2000; Trojano et al., 1999; Waubant et al., 1999) and in animal models of MS including experimental allergic encephalomyelitis (EAE) (Clements et al., 1997; Gijbels et al., 1993; Graesser et al., 1998 Graesser et al., , 2000 JovanovaNesic and Shoenfeld, 2006; Kieseier et al., 1998; Teesalu et al., 2001) , and are very closely linked to pathogenesis and disease progression. Elevated serum MMP activity is detectable extremely early in the disease course, being present even in Journal of Neuroimmunology 193 (2008) 
